MoonLake Immunotherapeutics - Class A — Cash Flow (NASDAQ:MLTX) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities —-611.07 K-55.89 M-42.78 M-116.59 M196.01 M 196.01 M Cash from investing activities —0-32.34 M-25.18 M-205.6 M202.99 M 202.99 M Cash from financing activities —-58.06 K119.69 M479.7 M51.31 M146 M 146 M Free cash flow —-611.07 K-55.91 M-43.06 M-117.11 M195.97 M 195.97 M

Nachrichten

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

Positive Studiendaten beflügeln MoonLake-Aktie

MoonLake stock surges on positive axSpA trial data

InvestingPro-Analyse prognostiziert Kurspotenzial: MoonLake-Aktie legt um 63 % zu

MoonLake stock surges 63% after InvestingPro Fair Value call

MoonLake: Positive Phase-2-Daten zu axialer Spondyloarthritis treiben Aktie an

MoonLake reports positive phase 2 axial spondyloarthritis data

ImageneBio beruft Dr. Porter-Brown zum neuen Chief Medical Officer

ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer

BTIG bestätigt Kaufempfehlung für Moonlake Immunotherapeutics vor wichtigen Studiendaten